McDonald Kerrie L, O'Sullivan Maree G, Parkinson Jonathon F, Shaw Janet M, Payne Cathy A, Brewer Janice M, Young Lawrence, Reader Dianne J, Wheeler Helen T, Cook Raymond J, Biggs Michael T, Little Nicholas S, Teo Charlie, Stone Glenn, Robinson Bruce G
Cancer Genetics, Kolling Institute of Medical Research, St. Leonards, New South Wales, Australia.
J Neuropathol Exp Neurol. 2007 May;66(5):405-17. doi: 10.1097/nen.0b013e31804567d7.
Clinical treatment decisions and the survival outcomes of patients with gliomas are directly impacted by accurate tumor classification. New and more reliable prognostic markers are needed to better identify the variable duration of survival among histologically defined glioma grades. Microarray expression analysis and immunohistochemistry were used to identify biomarkers associated with gliomas with more aggressive biologic behaviors. The protein expression of IQGAP1 and IGFBP2, when used in conjunction with the World Health Organization grading system, readily identified and defined a subgroup of patients with grade III gliomas whose prognosis was poor. In addition, in patients with glioblastoma multiforme, in whom IQGAP1 and IGFBP2 were absent, long-term survival of more than 3 years was observed. The use of these markers confirmed a nonuniform distribution of survival in those with World Health Organization grade III and IV tumors. Thus, IQGAP1 and IGFBP2 immunostaining supplements current histologic grading by offering additional prognostic and predictive information.
准确的肿瘤分类直接影响胶质瘤患者的临床治疗决策和生存结果。需要新的、更可靠的预后标志物，以更好地识别组织学定义的不同级别胶质瘤患者的不同生存时长。采用微阵列表达分析和免疫组织化学来识别与具有更具侵袭性生物学行为的胶质瘤相关的生物标志物。IQGAP1和IGFBP2的蛋白表达，与世界卫生组织分级系统一起使用时，能够轻松识别并界定出一组预后较差的III级胶质瘤患者。此外，在缺乏IQGAP1和IGFBP2的多形性胶质母细胞瘤患者中，观察到了超过3年的长期生存情况。这些标志物的使用证实了世界卫生组织III级和IV级肿瘤患者生存情况的分布并不均匀。因此，IQGAP1和IGFBP2免疫染色通过提供额外的预后和预测信息，补充了当前的组织学分级。
